Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer

Table 5 Crude and adjusted emergency department (ED) visits and hospitalization (H) incidence rates in study participants and contemporaneous controls by centre

	Number of patients	Total number of person-months	Emergency department visits				Hospitalizations
	Number of patients	Total number of person-months	Total ED visits	IR for ED visits per month	Crude IRR (95% CI)	Adjusted IRR^a (95% CI)	Total H visits	IR for H visits per month	Crude IRR (95% CI)	Adjusted IRR^b (95% CI)
Both centres
Control	215	860.3	257	0.30	1.00 (ref)	1.00 (ref)	59	0.07	1.00 (ref)	1.00 (ref)
AToM	77	338.7	50	0.15	0.48 (0.32, 0.73)	0.54 (0.36, 0.81)	24	0.07	1.05 (0.60, 1.85)	1.02 (0.59, 1.77)
Centre 1
Control	145	592.5	114	0.19	1.00 (ref)	1.00 (ref)	31	0.05	1.00 (ref)	1.00 (ref)
AToM	56	233.4	32	0.14	0.72 (0.46, 1.11)	0.78 (0.51, 1.21)	11	0.05	0.90 (0.45, 1.80)	0.96 (0.48, 1.95)
Centre 2
Control	70	267.8	143	0.53	1.00 (ref)	1.00 (ref)	28	0.10	1.00 (ref)	1.00 (ref)
AToM	21	105.3	18	0.17	0.29 (0.14, 0.62)	0.33 (0.16, 0.67)	13	0.12	1.27 (0.50, 3.19)	1.53 (0.65, 3.59)

ED emergency department visit, H hospitalization, IR incidence rate, IRR incidence rate ratio, CI confidence interval
^aRegression model controlled for age, cancer stage, initial chemotherapy regimen, and centre (where applicable)
^bRegression model controlled for age, cancer stage, initial chemotherapy regimen, history of ED use a year prior to diagnosis, and centre (where applicable)

ISSN: 2055-5784